Dexamethasone as an effective therapy for ocular injuries by vesicating agents

Ended Cooperative Agreement Awarded Last action

Award ID
U01EY030405
Recipient
Awarding agency
Obligated
$6,451,758

Award facts

Assistance listing
93.310 Trans-NIH Research Support
Completion date
Originally
Funding
  • $5,730,560.20 Federal
  • $721,198.00 Non-federal
Funding agency
Office of the Director National Institutes of Health, Department of Health and Human Services
Place of performance
Colorado, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment -$12,589 $0
Amendment $708,058 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $714,667 $0
Amendment $714,667 $0
Amendment $714,667 $0
Amendment $721,198 $0
Amendment $721,198 $0
Amendment $721,198 $721,198
Original award $727,496 $0
Show all 12

Subawards

Subrecipient Amount Awarded
Mriglobal Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents. $936

Quick answers

Who received award U01EY030405?

U01EY030405 was awarded to The Regents Of The University Of Colorado by National Eye Institute (National Institutes of Health) on August 1, 2020.

How much is award U01EY030405 worth?

$6,451,758 has been obligated on U01EY030405: $5,730,560 in federal funding and $721,198 in non-federal funding.

Which agency awarded U01EY030405?

National Eye Institute (National Institutes of Health) awarded U01EY030405, with funding from Office of the Director (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award